Kidney Fibrosis In Vitro and In Vivo Models: Path Toward Physiologically Relevant Humanized Models
Advanced Healthcare Materials, Volume 14, Issue 9, April 4, 2025.This review discusses kidney diseases with a focus on kidney fibrosis and the models currently used. It highlights the limitations of animal and 2D in vitro models in replicating human kidney anatomy and physiology. Consequently, there is a significant need for humanized 3D in vitro models, such as 3D cell aggregates, membranes and hydrogels, on‐chip ...
Gabriele Addario +2 more
wiley +1 more source
Changes in expression and activity of the secretory pathway Ca2+ATPase 1 (SPCA1) in A7r5 vascular smooth muscle cells cultured at different glucose concentrations [PDF]
, 2009 Diabetes mellitus-related vascular disease is often associated with both a dysregulation of Ca\(^{2+}\) homoeostasis and enhanced secretory activity in VSMCs (vascular smooth muscle cells).
Al-Bader +34 more
core +6 more sources
Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study [PDF]
, 2023 L Wolff Gowdak +14 more
openalex +1 more source
Pharmacoepidemiology and Drug Safety, Volume 34, Issue 3, March 2025.ABSTRACT Background Direct Healthcare Professional Communications (DHPCs) are an important risk minimisation measure. Their effect has been shown to be variable and has been measured using different outcomes and study populations. Depending on the content of the message, the optimal outcome to measure a direct effect of the DHPC can differ.
Esther de Vries +3 more
wiley +1 more source
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
Кардиоваскулярная терапия и профилактика, 2005 Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine.
L. V. Kremneva +2 more
doaj
Эффективность и безопасность триметазидина (Карметадина) в комплексном лечении больных с ишемической болезнью сердца и хронической сердечной недостаточностью [PDF]
, 2018 Целью исследования стало изучение эффективности и безопасности триметазидина (Карметадин, компания World Medicine) в комплексном лечении пациентов с ишемической болезнью сердца и хронической сердечной недостаточностью.
Гетман, М.Г. +4 more
core
Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy [PDF]
, 2015 Objectives: The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization.
Abozguia +25 more
core +1 more source
Sex Affects Myocardial Blood Flow and Fatty Acid Substrate Metabolism in Humans with Nonischemic Heart Failure [PDF]
, 2016 In animal models of heart failure (HF), myocardial metabolism shifts from the normal preference for high-energy fatty acid (FA) metabolism towards the more efficient fuel, glucose. However, FA (vs.
Coggan, Andrew R. +11 more
core +2 more sources
The Protective Eff ects Trimetazidine on Indomethacin Induced Gastric Ulcer in Rat Model
, 2023 Redhaa Imad, Huda I Al-Qadh
openalex +1 more source